Comparative Pharmacology
Head-to-head clinical analysis: KERYDIN versus LOPROX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KERYDIN versus LOPROX.
KERYDIN vs LOPROX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KERYDIN (tavaborole) is a boron-based antifungal that inhibits fungal protein synthesis by blocking the activity of leucyl-tRNA synthetase, thereby preventing aminoacylation of tRNA(Leu) and impairing protein synthesis in dermatophytes.
Ciclopirox is a hydroxypyridone antifungal agent that inhibits metal-dependent enzymes, including cytochromes, by chelating polyvalent cations (Fe3+, Al3+). It disrupts fungal cell membrane integrity and mitochondrial electron transport, leading to fungicidal activity. It also has anti-inflammatory properties by inhibiting prostaglandin and leukotriene synthesis.
8 mg/kg (max 800 mg) IV over 2 hours once daily for 14 days
Ciclopirox 1% cream or lotion: apply to affected area twice daily. Nail lacquer (8%): apply to affected nails daily. Shampoo (1%): apply 5-10 mL to wet scalp, lather, leave for 3 minutes, rinse; use twice weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours, supporting once-daily topical application.
Terminal elimination half-life is approximately 1.7 hours for the absorbed fraction, reflecting rapid renal clearance.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 88% of the dose, with negligible fecal excretion (<1% as unchanged drug).
Less than 1% of topically applied ciclopirox is absorbed; absorbed drug is conjugated and excreted renally as glucuronides, with minor fecal elimination.
Category C
Category C
Antifungal
Antifungal